Argyris Kyriakou

Dr. Argyris Kyriakou

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
MMMarios Markantonis
Marios Markantonis
PGPanos Georghiou
Panos Georghiou
FTFilippos Triposkiadis
Filippos Triposkiadis
AGAmalia Georgiou
Amalia Georgiou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Postoperative atrial fibrillation (POAF) is the most frequent post-cardiac surgical arrhythmia and is associated with haemodynamic instability, longer hospital stays, higher healthcare utilisation, stroke and adverse long-term outcomes. Conventional models of POAF focus on advancing age, pre-existing atrial substrate, increasing operative complexity, inflammatory responses related to cardiopulmonary bypass, disturbances in autonomic balance, and acute metabolic insults during the perioperative period. Although these explanations are important, they may be incomplete. Malignancy and the cancer-associated systemic environment involve biological processes potentially relevant to postoperative atrial vulnerability, such as chronic inflammation, oxidative stress, impaired vascular function, hypercoagulability, altered immune response, frailty, and treatment-related myocardial, pericardial, or conduction-system injury. This review assesses whether malignancy should be regarded as an underrecognised modifier of susceptibility rather than as a coincidental comorbidity. Most available data are extrapolated from cardio-oncology and thoracic oncology studies or general studies related to atrial fibrillation (AF) rather than studies focused on cardiac surgery. While malignancy cannot be dismissed as irrelevant to the generation of POAF, it also does not permit causal inference. Future studies should move beyond binary cancer status and incorporate cancer activity, treatment exposures, biomarker profiles, and atrial substrate measures to determine whether malignancy improves perioperative POAF risk stratification.

26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
AFArsene Fitzgerald Ferguson
Arsene Fitzgerald Ferguson
SKSotiris Kyriakou
Sotiris Kyriakou
AGAmalia Georgiou
Amalia Georgiou
AKArgyris Kyriakou
Argyris Kyriakou
FTFilippos Triposkiadis
Filippos Triposkiadis
Artificial intelligence (AI) and machine learning (ML) are increasingly being evaluated as decision-support tools for forecasting postoperative complications after cardiothoracic surgery. This narrative review synthesises peer-reviewed clinical, biomedical informatics, and digital-health literature across acute kidney injury (AKI), postoperative atrial fibrillation (POAF), pulmonary complications, neurological outcomes, mortality, wound monitoring, wearable surveillance, and post-discharge monitoring. Rather than treating reported AUC values as interchangeable evidence of algorithmic superiority, this review emphasises that model performance depends on at least three interacting factors: algorithmic architecture, data richness, and validation strategy. Conventional tools such as EuroSCORE II and Society of Thoracic Surgeons (STS) models remain clinically useful because they are familiar, transparent, and externally established; however, many rely on static perioperative snapshots and are less suited to continuously updated intraoperative and postoperative data streams. Contemporary ML models, including gradient-boosting approaches, support-vector methods, convolutional neural networks, and wearable-based algorithms, may improve discrimination in selected settings, particularly when dynamic laboratory trajectories, physiological time-series, imaging data, or remote-monitoring signals are available. However, current evidence remains limited by single-centre development, heterogeneous endpoints, inconsistent calibration reporting, limited decision-curve analysis, low positive predictive values in surveillance applications, and sparse prospective implementation. Future work should prioritise multicentre external validation, calibration, clinical utility analysis, standards-based electronic medical record interoperability, and implementation pathways that preserve clinician oversight.

17 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSotiris Kyriakou
Sotiris Kyriakou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
PGPanos Georghiou
Panos Georghiou
AKArgyris Kyriakou
Argyris Kyriakou
AGAmalia Georgiou
Amalia Georgiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Postoperative atrial fibrillation (POAF) after cardiac surgery is often managed as a transient inpatient arrhythmia, yet recurrent or silent atrial fibrillation (AF) after discharge may expose a vulnerable atrial substrate and change decisions about stroke prevention, anticoagulation and bleeding risk. This issue is particularly relevant in cancer survivors, in whom active malignancy, previous cardiotoxic therapy, frailty, anaemia, thrombocytopenia, hypercoagulability and planned oncological procedures can make standard POAF follow-up insufficient. This narrative review synthesises literature from POAF, cardio-oncology, wearable electrocardiographic monitoring and health informatics to examine whether digital rhythm surveillance could support post-discharge risk reassessment in this population. Direct evidence linking cancer, cardiac surgery, POAF and digital monitoring remains limited; therefore, the proposed “Digital Cancer-POAF Survivorship Pathway” is presented as a conceptual, hypothesis-generating framework for structured follow-up rather than as a validated clinical algorithm. Digital monitoring could improve detection of missed post-discharge AF, but only if results lead to clear clinical decisions, predefined AF-burden thresholds and prospective testing against clinical outcomes.

27 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
PGPanos Georghiou
Panos Georghiou
AGAmalia Georgiou
Amalia Georgiou
NINikolas Iosif
Nikolas Iosif
FTFilippos Triposkiadis
Filippos Triposkiadis
Cardiovascular disease remains Europe’s leading cause of death and disability despite mature evidence for prevention, acute and chronic treatment, rehabilitation, and secondary prevention. This structured critical narrative review evaluates whether the European Safe Hearts Plan can convert this evidence into coordinated, measurable, and accountable cardiovascular pathways. We appraise the plan’s ten flagship actions by evidence maturity and implementation readiness; distinguish shared system functions from disease-specific delivery for acute coronary syndromes, heart failure, and atrial fibrillation; compare selected European Society of Cardiology and American Heart Association/American College of Cardiology recommendations; and propose a core indicator set and staged Cyprus pilot. Guideline-supported interventions should be standardised and audited, whereas screening technologies, digital health, artificial intelligence, and novel phenotyping require governed implementation and prospective assessment of patient outcomes, costs, equity, and unintended consequences. Cyprus is presented as a bounded implementation setting rather than a directly generalisable European model. The plan should be judged through a limited set of clinical, implementation, and equity indicators, including premature cardiovascular mortality, risk factor control, guideline-directed therapy, rehabilitation participation, registry completeness, reach, and fidelity.

20 August 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
PGPanos Georghiou
Panos Georghiou
AKArgyris Kyriakou
Argyris Kyriakou
AGAmalia Georgiou
Amalia Georgiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Postoperative atrial fibrillation (POAF) after cardiac surgery is often managed as a transient inpatient arrhythmia, yet recurrent or silent atrial fibrillation (AF) after discharge may identify persistent atrial vulnerability. This issue is particularly relevant in cancer survivors, whose thrombotic and bleeding risks vary according to cancer activity, treatment exposure, thrombocytopenia, frailty and planned procedures. For this narrative review, PubMed/MEDLINE and Scopus were searched from inception to 16 June 2026, with Google Scholar used for supplementary citation tracking. A total of 50 publications were included in the final narrative synthesis. Direct evidence at the intersection of cancer, cardiac surgery, POAF and digital monitoring remains limited. Accordingly, the proposed “Digital Cancer-POAF Survivorship Pathway” is presented as a conceptual, hypothesis-generating framework, rather than a validated clinical algorithm. Its distinctive contribution is to connect cancer-state phenotyping and treatment-specific arrhythmic risk with post-discharge rhythm surveillance, electrocardiogram (ECG) confirmation, multidisciplinary interpretation, data governance and outcomes for prospective validation. Digital monitoring may increase AF detection; however, whether it reduces stroke, bleeding, readmission, or healthcare utilisation in this population is unknown. Neither a low detected AF burden nor the absence of AF during finite monitoring has been validated as an independent basis for anticoagulation decisions.

25 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSotiris Kyriakou
Sotiris Kyriakou
AKArgyris Kyriakou
Argyris Kyriakou
MNMarilina Neokleous
Marilina Neokleous
EBEREN OZAN BAKIR
EREN OZAN BAKIR
PAPetros Agathangelou
Petros Agathangelou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Percutaneous coronary intervention (PCI) treats focal coronary obstruction by compressing plaque, injuring the vessel wall and placing a metallic or bioresorbable scaffold. Most treated segments heal, but a small minority enter a prolonged, excessive or unstable repair state that contributes to in-stent restenosis (ISR), in-stent neoatherosclerosis and stent thrombosis (ST). Human evidence is strongest for delayed healing, uncovered struts, macrophage-rich neoatherosclerosis and hypersensitivity-associated late thrombosis, whereas routine immune biomarker-guided care remains unsupported. The narrowed lumen is only the visible endpoint; beneath it sits vascular repair shaped by de-vice-material exposure, local haemodynamics and host immunity. Endothelial denuda-tion and platelet activation initiate fibrin deposition, complement signalling and dam-age-associated molecular-pattern (DAMP) release. Neutrophils, monocytes and macro-phages dominate early, followed by lymphocytes and vascular smooth muscle cells that remodel the repair compartment. Drug-eluting stents (DES) have markedly reduced early neointimal hyperplasia, yet selected late failures still involve delayed endothelial recovery, chronic peristrut inflammation, hypersensitivity and neoatherosclerotic transformation. Immune biology is useful at the bedside only when interpreted with procedural context, device design and patient phenotype. Imaging-defined endpoints and paired immune phenotyping are therefore needed to guide treatment by mechanism instead of angiography or isolated biomarkers.